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Abstract 
Background: Intermittent preventive treatment (IPT) is a proven malaria control strategy in infants and pregnancy. 
School‑aged children represent 26 % of the African population, and an increasing percentage of them are scholarized. 
Malaria is causing 50 % of deaths in this age group and malaria control efforts may shift the malaria burden to older 
age groups. Schools have been suggested as a platform for health interventions delivery (deworming, iron‑folic acid, 
nutrients supplementation, (boost‑)immunization) and as a possible delivery system for IPT in schoolchildren (IPTsc). 
However, the current evidence on the efficacy and safety of IPTsc is limited and the optimal therapeutic regimen 
remains controversial.
Methods: A systematic search for studies reporting efficacy and safety of IPT in schoolchildren was conducted using 
PubMed, Web of Science, Clinicaltrials and WHO/ICTRP database, and abstracts from congresses with the following 
key words: intermittent, preventive treatment AND malaria OR Plasmodium falciparum AND schoolchildren NOT infant 
NOT pregnancy.
Results: Five studies were identified. Most IPTsc regimes demonstrated substantial protection against malaria parasi‑
taemia, with dihydroartemisinin‑piperaquine (DP) given monthly having the highest protective effect (PE) (94 %; 95 % 
CI 93–96). Contrarily, SP did not provide any PE against parasitaemia. However, no IPT regimen provided a PE above 
50 % in regard to anaemia, and highest protection was provided by SP+ amodiaquine (AQ) given four‑monthly (50 %; 
95 % CI 41–53). The best protection against clinical malaria was observed in children monthly treated with DP (97 %; 
95 % CI 87–98). However, there was no protection when the drug was given three‑monthly. No severe adverse events 
were associated with the drugs used for IPTsc.
Conclusion: IPTsc may reduce the malaria‑related burden in schoolchildren. However, more studies assessing effi‑
cacy of IPT in particular against malaria‑related anaemia and clinical malaria in schoolchildren must be conducted.
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Background
Malaria is a major public health problem in sub-Saha-
ran Africa (SSA), with 90  % of the burden occurring in 
African children [1–3]. To date, development and imple-
mentation of interventions for malaria prevention and 
control have been mainly directed towards well-known 
risk groups, such as pregnant women and children 
younger than 5  years old [4]. However, the impact of 
health factors on educational outcomes for schoolchil-
dren is widely recognized, including by governments [5]. 
Previous research on the effect of malaria on children’s 
education showed that malaria is the leading cause of 
school absenteeism [6, 7] and asymptomatic malaria 
was likely to affect school performance [8]. In addition, 
malaria remains the biggest killer among school-aged 
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children, causing 50 % of deaths in this age group in sub-
Saharan Africa [9]. School-aged children represent 26 % 
of the African population, and an increasing percentage 
of them are scholarized. Since 2000, school enrolment 
increased by 52 % in sub-Saharan Africa [10]. Moreover, 
studies suggest that increasing control efforts and sub-
sequent decline of the malaria burden as well as further 
progress towards malaria elimination will lead to a shift 
of at-risk population from under-five to older children 
groups, to which schoolchildren belong [11, 12]. Little 
research assesses adapted intervention tools for this vul-
nerable target group. Effective control measures could 
indeed reduce the burden of malaria in school-aged chil-
dren. Sleeping under insecticide-treated nets can reduce 
overall child mortality [13]. Unfortunately, schoolchildren 
seem to be less likely to sleep under a bed net than those 
under-5 years old [14]. Active screening and treatment is 
another strategy under investigation. This approach may 
raise the question of the appropriate test to track asymp-
tomatic malaria, since the latter is generally associated 
with relatively low parasite density [15]. Intermittent pre-
ventive treatment (IPT) may be another promising thera-
peutic strategy to prevent malaria and its related adverse 
outcomes in school-aged children [16]. This strategy has 
largely been studied in groups bearing the highest burden 
of the disease. In infants (IPTi), children younger than 
5 years (IPTc) and pregnant women (IPTp), IPT schemes 
have been demonstrated to be protective against malaria 
and its related adverse outcomes [17–21]. However, only 
a handful of studies have focused on the potential ben-
efits of IPT on school-aged children’s health (IPTsc). This 
review summarizes published results of this subject and 
it presents efficacy and safety data for all available thera-
peutic regimes in order to produce more information on 
their impact on asymptomatic and symptomatic parasi-
taemia, and haemoglobin concentration.
Methods
Search strategy and selection criteria
A single investigator (JMR) developed and conducted a 
systematic literature search for published IPTsc studies, 
on 28 April, 2014. Studies were identified using Pub-
Med, Web of Science, Clinicaltrials [Clinicaltrials.gov 
and World Health Organization international clinical 
trials registry platform (WHO ICTRP) database] and 
abstracts from congresses. Combinations of the following 
search terms were used: intermittent, preventive treat-
ment AND malaria OR Plasmodium falciparum AND 
schoolchildren NOT infant NOT pregnancy. Study eli-
gibility was assessed in an unblinded manner. Studies 
had to be published articles written in English. Inclu-
sion criteria were determined following the PICO for-
mat: (P) Participants: children of school age, resident in 
a malaria-endemic area; (I) Interventions: clinical trials 
evaluating the efficacy and safety of IPT; (C) Compari-
sons: the efficacy of available drug regimes compared to 
each other or with placebo; (O) Outcomes: the propor-
tion of children with parasitaemia, anaemia and clinical 
malaria to provide the effect estimates (or sufficient data 
for calculation of an effect estimate), relative risk (RR), 
protective effect (PE), and their corresponding 95 % con-
fidence interval (CI). If a selected study included more 
than one comparator or drug regimen, each comparison 
was regarded as a separate study. Studies which enrolled 
children younger than 5  years were included if data on 
children over 5  years were available for analysis. Stud-
ies evaluating chemoprophylaxis, screening and prompt 
treatment, as well as study protocol, were excluded.
Data extraction
All the titles and abstracts were collected through the 
electronic search and filtered for potentially eligible 
articles. For each study, the following information was 
extracted: first author, publication year, year of study start 
and end, study design, randomization procedures, inclu-
sion criteria, insecticide-treated net or bed-net use, local 
malaria transmission details of study groups, number of 
enrolled children, outcomes assessed and adverse events. 
Data from eligible studies were extracted based on the 
intention to-treat principle into a purpose-built database 




A total of five trials assessing the efficacy of IPT for pre-
venting asymptomatic and clinical malaria and anaemia 
in school-aged children were identified and included 
for analysis (Fig. 1) [23–27]. The trials were undertaken 
in Bondo in Kenya, in Kambila in Mali, Kollé in Mali, 
and in Tororo in Uganda. Malaria transmission patterns 
ranged from seasonal in the Malian sites over perennial 
with seasonal peaks in Kenya to hyperendemic in Tororo, 
Uganda. Usage of bed nets was low (<5–35.4 %) in all tri-
als. All trials were randomized and placebo controlled, 
except for Kimbila (Mali), which was randomized and 
controlled. Two were double blinded, two open and one 
single blinded. Block randomization by individual was 
done in all trials except for Bondo (Kenya), which was 
cluster-randomized by schools.
IPT schedules differed between trials and were given 
every 5 months, four-monthly, three-monthly, bimonthly, 
monthly, or only at baseline (Table 1). All five trials had 
received ethics approval. The efficacy and safety of sulf-
adoxine-pyrimethamine (SP) was assessed in four trials: 
alone [23, 26], combined with amodiaquine (SP +  AQ) 
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[24], or with artesunate (SP  +  AS) [25]. Other combi-
nations used were AQ  +  AS [25]. Dihydroartemisinin-
piperaquine (DP) monotherapy was used in two trials in 
different schedules: at baseline, monthly and trimonthly 
[26, 27]. Safety and efficacy were assessed by passive and 
active clinical surveillance in all trials. The primary end-
point was the incidence of clinical malaria in three trials 
[23, 25, 27]. One trial’s primary endpoint was the risk of 
asymptomatic parasitaemia at 42 days [26] and the trial 
conducted in Bondo (Kenya) had the prevalence of anae-
mia as primary endpoint. However, three trials assessed 
the prevalence of anaemia or the increase in haemoglo-
bin concentration as secondary endpoint [25–27]. The 
study duration differed between trials. Three trials eval-
uated the efficacy and safety of IPTsc on the basis of a 
12 months’ follow-up [23, 24, 27], whereas in the remain-
ing trials the follow-up period was of 5 months [25] and 
42 days [26]. Thick blood films were stained and read by 
use of standard procedures for malaria parasite detec-
tion in all trials. Parasite density was calculated on the 
assumption of a mean of 8000 leucocytes/µL in two tri-
als, or a mean of 7500 leucocytes/µl in Kambila (Mali) 
trial, whereas two trials did not specify the number of 
leucocytes for the parasite density calculation. The hae-
moglobin concentration was measured with a Hemocue® 
photometer in all trials. Data on anaemia were reported 
in three of them [24, 25, 27]. Anaemia was defined as 
haemoglobin <11.0  g/dL [24, 25] and haemoglobin 
<11.5  g/dL for children aged 6–11  years and <12.0  g/
dL for those aged 12–14  years [27]. The frequency and 
112 citations remained after 
duplicates removed  
11 citations were selected for 
more detailed assessment  
Others citations excluded:
3 chemoprophylaxis 
1 prompt treatment study
1 study protocol
101 citations did not address 
the study question and were 
excluded  
5 full- text were included for 
analysis




14 citations were 
identified from Clinical 
trials: 9 from 
clinicaltrials.gov and 5 
from WHO ICTRP  
123 citations were 
identified from Web of 
Science database  
100 citations were identified from 
PubMed database Citations remained 
after duplicates removed    
Fig. 1 Flow chart study selection process of studies assessing efficacy of intermittent preventive treatment (2015)
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timing of outcome measurement varied greatly between 
studies. Malaria parasitaemia was assessed on days 7, 14, 
28, and 42 [26] and monthly [25, 27]. The haemoglobin 
level was measure on day 42 [26], 6 weeks after the last 
treatment [24], every 3 and 5 months [27] and monthly 
[25]. Monitoring for clinical malaria was by active case 
detection [27], by active weekly follow-up visits and pas-
sive follow-up [23] and active monthly follow-up visits 
and passive follow-up [25].
Efficacy of IPTsc on malaria parasitaemia
IPT with SP combined with AS and AQ +  AS reduced 
significantly the risk of malaria parasitaemia. The prev-
alence of parasitaemia by treatment group was 6.6, 
6.2 and 34.4  % for SP +  AS, AQ +  AS and vitamin C, 
respectively (P  <  0.001) [25]. The risk of parasitaemia 
in DP and AQ  +  SP groups (11.7 and 44.3  %, respec-
tively) was significantly lower than in those receiving SP 
(79.7 %) (risk difference AQ + SP vs placebo: 68.0 %; 95 % 
CI 60.6–75.4, p < 0.001; DP vs placebo: 35.4 %; 95 % CI 
26.3–44.5, p < 0.001), and SP vs placebo: −4.9 %; 95 % CI 
−12.6 to 2.9, p = 0.2). DP was superior to AQ + SP (risk 
difference 32.6 (95  % CI 24.3–40.9); p  <  0.001) [26]. SP 
plus AQ administered four-monthly reduced the preva-
lence of parasitaemia (SP + AQ: 4.6 %; 95 % CI 0.8–14.1) 
vs placebo: 39.7 %; 95 % CI 26.2–58.1 %, p < 0.0001) in 
Bondo, Kenya. The prevalence of parasitaemia was 
2 % in DP monthly arm, 18 % in DP three-monthly and 
38  % in control arm, in Uganda, 2014. The IPTsc with 
SP monotherapy in Tororo, Uganda did not demon-
strate any PE against parasitaemia (0.05  %; 95  % CI −4 
to 14). The PE of SP  +  AQ administered four-monthly 
was 88 % (95 % CI 86–90) in Bondo, Kenya, but this drug 
regimen demonstrated a lower PE (49 %; 95 % CI 38–56) 
in Tororo, Uganda. SP + AS and AQ + AS administered 
in Mali demonstrated similar PE (81 % (95 % CI 56–92) 
and 81 % (95 % CI 57–91), respectively. The PE of DP in 
Tororo in 2010 was 86 % (95 % CI 80–91) after 42 days’ 
follow-up. In 2014 the PE of DP given monthly in Tororo 
was the highest (94  %; 95  % CI 93–96), but this same 
drug regimen administered three-monthly in Tororo in 
2014 had a significantly lower PE of 54 % (95 % CI 49–58) 
(Fig. 2; Table 2).
Efficacy of IPTsc on anaemia
Children treated with IPT were significantly less likely to 
be anaemic (SP + AS, 17.7 %; AQ + AS, 16.0 %; vitamin 
C, 29.6 %; P = 0.039) in Kollé, Mali. In Tororo, Uganda 
(2014), the prevalence of anaemia was significantly lower 
in the DP given monthly arm (12 %) but not the DP given 
three-monthly arm (17  %), compared with the placebo 
arm (20 %). SP + AQ (given four-monthly) reduced sig-
nificantly the risk of anaemia (6.3  %), in Bondo, Kenya 
(SP + AQ: 6.3 % vs placebo: 12.6 %; p = 0.041). The PE 
effect of IPTsc on anaemia was generally lower in all trials 
that assessed this endpoint, and ranged from 14 to 50 %. 
SP + AQ (given three-monthly), SP + AS, AQ + AS and 
DP (administered monthly) demonstrated similar PE of 
IPTsc against anaemia in schoolchildren. The PE effect of 
DP given three monthly was the lowest (14  %; 95  % CI 
2–23) (Table 3). The change in mean haemoglobin level 
did not differ between children who received SP  +  AS 
and AQ  +  AS, compared to those receiving placebo in 
Kollé, Mali. In Tororo as well, SP in 2010 and DP given 
three-monthly in 2014 did not increase the mean haemo-
globin level compared to placebo. However, in the same 
Table 2 Effect of IPTsc on malaria parasitaemia during the intervention period
PE protective effect, No number, SP sulfadoxine-pyrimethamine, SP + AQ sulfadoxine-pyrimethamine plus amodiaquine, SP + AS sulfadoxine-pyrimethamine plus 
artesunate, AQ + AS amodiaquine plus artesunate, DP dihydroartemisinin-piperaquine, % percentage
a Total tests 
Study site Study by drug regimen No. of children Prevalence of infection (%) PE (95 % CI)
Clarke [24] Bondo SP + AQ (four‑monthly) 2584 4.6 88 (86 to 90)
Placebo 2294 39.7 –
Barger [25] Kollé SP + AS 91 6.6 81 (56 to 92)
AQ + AS 97 6.2 81 (57 to 91)
Placebo 96 34.4 –
Nankabirwa [26] Tororo SP 186 79.7 0.05 (−4 to 14)
SP + AQ 200 43.3 49 (38 to 56)
DP 198 11.7 86 (80 to 91)
Placebo 196 84.6 –
Nankabirwa [27] Tororo DP (monthly) 2638a 2 94 (93 to 96)
DP (three to five monthly) 2644a 18 54 (49 to 58)
Placebo 2700a 38 –
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trials held in Tororo, IPTsc with DP and SP  +  AQ (in 
2010) increased the mean haemoglobin level (mean dif-
ference: 0.37 g/dL (95 % CI 0.18, 0.56) and 0.34 g/dL (95 % 
CI 0.15, 0.53), respectively) compared to baseline. Simi-
larly, DP given monthly (in 2014) significantly increased 
the mean haemoglobin level compared to placebo group 
(1.20 vs 0.79 g/dL; P = 0.003). A high mean haemoglobin 
level was also observed in children treated with SP + AQ 
compared to those in placebo group (mean difference: 
5.62 g/L (95 % CI 2.19–9.05) in Bondo, Kenya (Fig. 3). 
Efficacy of ITPsc on clinical malaria
The PE of IPTsc with SP given bimonthly against clinical 
malaria was 40.1 % (95 % CI 17.9–56.4) in Kambila, Mali. 
The PE of SP + AS in Mali was 67 % (95 % CI: 42–98). 
In the trial conducted in Kollé, Mali, AQ + AS had a PE 
of 47  % (95  % CI 32–67). In 2014 DP given monthly in 
Tororo had the highest PE (97 %; 95 % CI 87–98), how-
ever, this same drug regimen administered three- to five-
monthly in Tororo in 2014 had a no PE (Fig. 4; Table 4).
Safety outcome
Seven deaths occurred in the trial conducted in Bondo, 
Kenya, two in the IPT group and five in the placebo group. 
Cause of death could not be reliably ascertained in all cases. 
Twenty-three drug-related severe adverse events were 
observed during this study. Of these 23 adverse events, 
19 occurred in the IPTsc goup (SP + AQ three-monthly) 
and four in the placebo group. The most commonly severe 
adverse events were: problems of balance, dizziness, feel-
ing faint, nausea, or vomiting. One severe skin reaction 
was reported in the placebo group. In the study conducted 
Fig. 2 Effect of IPTsc on malaria parasitaemia during the intervention period. RR rate ratio, SP sulfadoxine‑pyrimethamine, SP + AQ sulfadoxine‑
pyrimethamine plus amodiaquine, SP + AS sulfadoxine‑pyrimethamine plus artesunate, AQ + AS amodiaquine plus artesunate, DP dihydroarte‑
misinin‑piperaquine, CI confidence interval
Table 3 Effect of IPTsc on anaemia during the intervention period
PE protective effect, No number, SP + AQ sulfadoxine-pyrimethamine plus amodiaquine, SP + AS sulfadoxine-pyrimethamine plus artesunate, AQ + AS amodiaquine 
plus artesunate, DP dihydroartemisinin-piperaquine, % percentage
a Total tests
Study site Drug regime No of children Prevalence of anaemia (%) PE (95 % CI)
Clarke [24] Bondo SP + AQ (four‑monthly) 2604 6.3 50 (41–53)
Placebo 2302 12.6 –
Barger [25] Kollé SP + AS 96 17.7 40 (9–61)
AQ + AS 100 16 46 (17–65)
Control 98 29.6 –
Nankabirwa [27] Tororo DP (monthly) 717a 12 40 (29–49)
DP (three and five monthly) 716a 17 14 (2–23)
Placebo 736a 20 –
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in Tororo, Uganda, 2014, one death occurred in the IPT 
intervention group (DP three-monthly) due to acute 
lymphoblastic leukaemia. Fourteen severe adverse events 
were observed, but were judged unlikely to be associ-
ated with treatment. In almost all trials, mild or moderate 
adverse events were frequent in IPT group compared to 
placebo group. However, in the study conducted in Tororo 
(2014), mild or moderate adverse events including: fever, 
headache, nausea and vomiting were commonly associated 
with malaria, and were more frequent in placebo group 
than in the intervention arms. SP + AQ was significantly 
associated with vomiting in Tororo, 2010, and AQ + AS 
had the highest rate of headache in Kollé (Table 5).
Discussion
The aim of this review was to provide an overview of 
the effectiveness of IPT to prevent parasitaemia, clini-
cal malaria and malaria-related anaemia in older chil-
dren and to find out the most promising drug regimen 
for IPT in this specific population. The most appropri-
ate drug regimen for IPTsc should provide protection 
against malaria-related anaemia and asymptomatic 
malaria parasitaemia, as these are the main features of 
malaria in this specific population. In this review, the 
studies used a wide variety of IPT regimes incorporat-
ing different drugs, dosages, timings, and numbers of 
IPT rounds.
Fig. 3 Effect of IPTsc on anaemia during the intervention period. RR rate ratio, SP sulfadoxine‑pyrimethamine, SP + AQ sulfadoxine‑pyrimethamine 
plus amodiaquine, SP + AS sulfadoxine‑pyrimethamine plus artesunate, AQ + AS amodiaquine plus artesunate, DP dihydroartemisinin‑piperaquine, 
CI confidence interval
Table 4 Effect of IPTsc on clinical malaria during the intervention period
PE protective effect, No number, SP sulfadoxine-pyrimethamine, SP + AQ sulfadoxine-pyrimethamine plus amodiaquine, SP + AS sulfadoxine-pyrimethamine plus 
artesunate, DP dihydroartemisinin-piperaquine, … data not available, PYAR person-year at risk
a 5–10 years sub-group
Study site Drug regime No of children Incidence rate per 1000 PYAR PE (95 % CI)
Dicko [23] Kambila SP (bimonthly) … 2.7a 40.1 (17.9–56.4)
Control … 4.5a –
Barger Barger [25] Kollé SP + AS 91 488 67 (42–98)
AQ + AS 97 782 47 (32–67)
Placebo 96 1463 –
Nankabirwa [27] Tororo DP (monthly) 236 0.01 97 (87–98)
DP (three and five monthly) 234 0.34 0.00
Placebo 243 0.34 –
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The PE of IPT against malaria parasitaemia ranged 
from 49 to 94 % in the trials that assessed this endpoint. 
The highest PE was observed using DP monthly. SP + AQ 
given four-monthly, also demonstrated a high PE. SP 
monotherapy provided the lowest PE against malaria 
parasitaemia. This low efficacy of SP is not surprising 
and highlights the wide spread of resistance to this drug 
across Africa. The prevalence of 540E, one of the key SP 
resistance mediators, was found to be less than 50 % in 
Mali, whereas high prevalence of this marker (above 
50  %) was observed in Uganda and Kenya [28]. This is 
in agreement with other findings from trials conducted 
in children younger than 5 years [29]. DP given monthly 
in Tororo, 2014, showed the highest PE against clinical 
malaria, but this drug given three-monthly did not show 
any PE against clinical malaria. These results are consist-
ent with the theory stipulating that IPT protects by pro-
viding a period of post-treatment prophylaxis and that 
the length of this period of protection is determined by 
the pharmacodynamics of the drugs used [30].
The protective effect of IPTsc against malaria-related 
anaemia was relatively low in most trials that assessed 
this endpoint. DP given three- to five-monthly had the 
lowest PE against anaemia while DP given three- to five-
monthly, or SP + AS and AQ + AS did not demonstrate 
any superiority in terms of mean change in haemoglobin 
levels compared to placebo. However, the combination 
of two drugs with long half-life (SP + AQ) in two stud-
ies [24, 26] increased the mean haemoglobin level com-
pared to placebo. This relative low PE of ITPsc regimes 
on anaemia could be, at least partly, explained by the fact 
that haemoglobin or haematocrit continue to fall after 
treatment and may return to the normal level within 
1 month from the start of malaria treatment. Moreover, 
malaria recrudescence has been found to delay haemato-
logical recovery [31]. Also, more importantly, the nega-
tive effect of malaria parasitaemia on heamoglobin level 
has been shown to decrease with age [32], suggesting 
that IPT would have a relatively low impact on malaria-
related anaemia in schoolchildren. However a low PE of 
IPT against anaemia has also been observed in infants 
[33]. This adds more evidence on the expected efficacy of 
long half-life drug to protect against malaria parasitaemia 
recrudescence and thus against malarial anaemia. Given 
that malaria-related anaemia is multifactorial, involving 
haemolysis, iron deficiency due to impaired intestinal 
iron absorption, and red cell production failure (RCPF) 
[34, 35], the supplementation of ingested iron may rap-
idly replenish red blood cells (RBCs) and shorten hae-
matological recovery after malaria infection has been 
cleared.
No deaths could be attributed to administration of 
drugs for IPTsc and observed severe adverse events 
occurred in both interventions and control groups. How-
ever, some adverse events judged mild or moderate were 
more frequent in intervention groups in one study.
Based on these findings, SP monotherapy should be 
considered the worst therapeutic regimen for IPTsc 
in area of high resistance to SP. However, SP has sev-
eral benefits, including its low cost and proven safety. 
Fig. 4 Effect of IPTsc on clinical malaria during the intervention period. IRR incidence rate ratio, SP sulfadoxine‑pyrimethamine, SP + AS sulfadoxine‑
pyrimethamine plus artesunate, AQ + AS amodiaquine plus artesunate, DP dihydroartemisinin‑piperaquine, CI confidence interval
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Moreover, studies have shown that SP could still be effec-
tive even in the presence of a high level of resistance in 
adults [36]. The underlying explanation could be that 
immunity increases with age and may modify the effect 
of anti-malarial drugs [37]. On the other hand, DP and 
SP  +  AQ appear to be the most promising drug regi-
men for IPTsc. However, given that the effect of IPT is 
mainly prophylactic, short-acting drugs such as artem-
esinins would be expected to provide little direct benefit 
in asymptomatic children and monthly administration 
of such drugs, though effective, may be challenging and 
costly. Moreover, the drug pressure in the context of 
IPT may lead to an increase of the selection of mutants 
resistant to artemisinin. Therefore, combination of SP 
with another long half-life such as piperaquine (PQ), AQ 
or mefloquine may be better option for investigation in 
clinical trials in schoolchildren. An additional advantage 
of combining two long half-life drugs is the reduction of 
risk of resistance to the two drugs as they have similar 
elimination half-lives [38]. IPT using long half-life drugs 
also appears to be more realistic in terms of frequency of 
drug administration, which can be bi- or three-monthly, 
and in children compliance.
This review suggests a need for harmonization in 
regard to the timing and frequency of drug administra-
tion as well as the time frame for drug evaluation in the 
context of IPT. IPT describes the administration of a drug 
at specified time intervals, allowing a very low concen-
tration of drug (below the inhibitory level) between two 
treatments, with the aim of preventing mortality or mor-
bidity. This should differ from chemoprophylaxis where 
the drug concentration is maintained above the level 
that inhibits parasitic growth [16]. A great variation in 
IPT drug timing and frequency of administration as well 
as the time frame for evaluation of IPT between studies 
has been observed, suggesting some overlaps between 
IPT and chemoprophylaxis. When a long-acting drug 
such as SP or piperaquine is used for IPT, a protective 
blood concentration may be sustained for several weeks, 
thus providing a period of chemoprophylaxis. Dicko 
et al. evaluated the efficacy of the SP administered every 
2 months [23]. Given the long half-life of SP, this clinical 
trial should be considered evaluating chemoprophylaxis 
based on SP, rather than an IPT. In fact, a study con-
ducted in the context of high resistance of SP reported 
that SP offered optimum protection until the fifth week 
after administration and that protection disappeared 
after the eighth week [30]. Similarly, the time frame for 
the evaluation of IPT should differ from that of chemo-
prophylaxis. An evaluation occurring when the drug con-
centration is optimal or above the minimum inhibitory 
concentration (MIC) would account for the effectiveness 
of chemoprophylaxis rather than an IPT.
Beside the choice of the appropriate drug regimen, one 
would anticipate the feasibility of this strategy. Schools 
have been suggested as a platform for health intervention 
delivery (deworming, iron-folic acid, nutrients supple-
mentation, (boost-immunization). These interventions 
have been shown to improve not only children’s health 
and nutrition, but also their learning ability [39, 40]. 
Therefore, the increasing number of children of school-
age and a higher number of these children attending a 
primary school [41] combined with the known impact of 
malaria on school-aged children’s health reasonably sug-
gests that IPTsc could be part of the package of school 
health intervention, if this benefit is sufficiently proven.
The present study has a number of limitations. Since 
the search focused on the Pubmed database and articles 
published in English, there is a risk some other stud-
ies are missing. However, this is unlikely given the very 
limited number of trials conducted on IPTsc. Individual 
patient data were unavailable, therefore, the effect of 
baseline parasitaemia, age, ITN usage, or nutritional sta-
tus on the efficacy of IPT could not be assessed. The high 
variability (heterogeneity in clinical, methodological and 
statistical aspects) across studies precludes a meta-analy-
sis. Moreover, the small number of available studies could 
not allow a pooled analysis in sub-group regimes. There-
fore, protective effect of regimes vs placebo or controls 
against clinical or asymptomatic malaria and anaemia 
were assessed without combined estimates.
Conclusion
This systematic review found only five studies assessing 
the efficacy of IPTsc. Today, SP may not be a promising 
regimen for IPTsc in areas where resistance to this drug 
is high. Arteminisinin combination therapies (ACTs) (DP, 
SP + AS, AQ + AS) provided acceptable protective effi-
cacy against clinical malaria, parasitaemia and anaemia. 
DP administered monthly demonstrated the highest PE. 
However, acceptability, feasibility and thus, effective-
ness of a monthly administration of IPTsc is not known. 
Further, ACT is used for curative purposes. Combining 
at least two long half-life drugs, such as piperaquine plus 
SP may be, at present, the most promising option. More 
studies assessing efficacy of IPTsc in particular against 
malaria-related anaemia and clinical malaria must be 
conducted.
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